Now that clinicians outside of hospital settings can assess and treat HCV in France, which high-risk groups should we target for HCV “microelimination” and how? Here’s my take.
HCV prevalence remains high among PWID and incarcerated individuals in Germany, as barriers to care persist. How can we best provide both HCV treatment and harm reduction services to these key populations? Here’s my take.
Spain has the highest HCV treatment rate among European nations, yet challenges remain for our goal of eliminating HCV by 2030. Read my take on how we should best implement national strategies at the local level in high-priority populations.
Outdated regulatory barriers stand in the way of ready access to DAA therapy in Italy. How can we best reform these policies (eg, complex pretreatment characterization, prescriber restrictions) to treat more PWID and move closer to HCV elimination? Here’s my take.
The promising HCV treatment as prevention (TasP) model has yet to be proven in real-world PWID. Here, we share our experiences, progress, and remaining challenges with evaluating a local HCV TasP program in Tayside, Scotland.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.